Summaries for patients. Treatment of refractory thrombotic thrombocytopenic purpura.
D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000276:immunology; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008666:Metalloendopeptidases / Q000172:deficiency / Q000276:immunology; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D014841:von Willebrand Factor / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D014841:von Willebrand Factor; D000069283:Rituximab; D003520:Cyclophosphamide; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human